Quick Takeaways
- Vivo Opportunity Fund Holdings, L.P. filed SCHEDULE 13G/A for Unicycive Therapeutics, Inc. Common Stock, $0.001 par value per share (UNCY).
- Disclosed ownership: 10%.
- Date of event: 31 Mar 2025.
Vivo Opportunity Fund Holdings, L.P. - 31 Mar 2025 SCHEDULE 13G/A Report for Unicycive Therapeutics, Inc. Common Stock, $0.001 par value per share (UNCY)
- Filing Manager
- Vivo Opportunity Fund Holdings, L.P.
- Reporting Manager
- Vivo Opportunity Fund Holdings, L.P.
- Symbol
- UNCY
- Shares outstanding
- 610,227,518 shares
- Disclosed Ownership
- 60,961,729 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 08:30:31 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Vivo Opportunity Fund Holdings, L.P. disclosed 10% ownership in Unicycive Therapeutics, Inc. Common Stock, $0.001 par value per share (UNCY) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 08:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | 60,961,729 | 60,961,729 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member | |
| Vivo Opportunity, LLC | 10% | 60,961,729 | 60,961,729 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member |